SUMATRIPTAN; NAPROXEN SODIUM
Clinical safety rating: avoid
Other 5-HT1 agonists and MAOIs can have additive effects Contraindicated in ischemic heart disease and uncontrolled hypertension.
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
| Metabolism | Sumatriptan is primarily metabolized by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9. |
| Excretion | Sumatriptan: renal excretion of unchanged drug and metabolites (primarily indole acetic acid analogue) accounts for approximately 60% of elimination; fecal/biliary excretion accounts for about 40%. Naproxen sodium: renal excretion of unchanged drug (approximately 60%) and glucuronide conjugates (about 40%); less than 5% is excreted fecally. |
| Half-life | Sumatriptan: terminal half-life approximately 2.5 hours (range 1.5–4.6 hours); clinically, short half-life limits duration of action. Naproxen sodium: terminal half-life approximately 12–17 hours (mean 14 hours); long half-life allows twice-daily dosing and sustained analgesic effect. |
| Protein binding | Sumatriptan: protein binding approximately 14–21% (low binding). Naproxen sodium: protein binding >99% (highly bound to albumin). |
| Volume of Distribution | Sumatriptan: Vd approximately 2.2 L/kg (indicates extensive tissue distribution). Naproxen sodium: Vd approximately 0.16 L/kg (low Vd, consistent with high protein binding and limited tissue distribution). |
| Bioavailability | Sumatriptan: oral bioavailability approximately 15% (due to first-pass metabolism); subcutaneous injection 96%; intranasal approximately 17%. Naproxen sodium: oral bioavailability >95% (well absorbed). |
| Onset of Action | Sumatriptan: oral tablets onset in 30–60 minutes; subcutaneous injection onset in 10–15 minutes; intranasal spray onset in 15–30 minutes. Naproxen sodium: oral onset within 1 hour; peak effect in 2–4 hours. |
| Duration of Action | Sumatriptan: duration of action 2–4 hours for headache relief; recurrence common due to short half-life. Naproxen sodium: duration of action up to 12 hours due to long half-life; provides sustained anti-inflammatory and analgesic effect. |
Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if GFR <30 mL/min; for GFR 30-50 mL/min, caution with naproxen component; no specific dose adjustment recommended for sumatriptan. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C); sumatriptan maximum dose 50 mg per dose in moderate impairment (Child-Pugh class B); naproxen sodium avoid in severe impairment. |
| Pediatric use | Not approved for patients <12 years; for adolescents 12-17 years, single dose of sumatriptan 85 mg / naproxen sodium 500 mg (as adult formulation) per clinical judgment, not to exceed 1 dose in 24 hours. |
| Geriatric use | Avoid use in elderly due to increased risk of cardiovascular events, gastrointestinal bleeding, and renal impairment; if necessary, use lowest effective dose for shortest duration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other 5-HT1 agonists and MAOIs can have additive effects Contraindicated in ischemic heart disease and uncontrolled hypertension.
| FDA category | Contraindicated |
| Breastfeeding | Sumatriptan: Excreted in breast milk with estimated relative infant dose of 3.5% of maternal weight-adjusted dose; M/P ratio not well defined. Naproxen: Excreted in breast milk with M/P ratio approximately 0.01; relative infant dose <1% of maternal dose. Both considered compatible with breastfeeding with monitoring for infant adverse effects. |
| Teratogenic Risk |
■ FDA Black Box Warning
Cardiovascular and gastrointestinal risks: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. NSAIDs also increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Sumatriptan is contraindicated in patients with history of coronary artery disease or risk factors. Do not use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication.
| Common Effects | Chest pain |
| Serious Effects |
["History of coronary artery disease (CAD) or coronary artery vasospasm","Wolff-Parkinson-White syndrome or other cardiac accessory pathway disorders","History of stroke or transient ischemic attack","Peripheral vascular disease","Ischemic bowel disease","Uncontrolled hypertension","Within 24 hours of treatment with another 5-HT1 agonist (e.g., triptans) or ergotamine-containing medications","Concomitant use or within 2 weeks of MAO-A inhibitor","History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs","In the setting of coronary artery bypass graft (CABG) surgery","Third trimester of pregnancy"]
Loading safety data…
| Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction and reduced placental perfusion. Naproxen: First trimester – potential increased risk of cardiac defects; second trimester – generally safe with caution; third trimester – contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal renal dysfunction. |
| Fetal Monitoring | Monitor maternal blood pressure, uterine artery Doppler if preeclampsia risk, fetal growth and amniotic fluid volume if naproxen used beyond 20 weeks. Assess for signs of bleeding or premature closure of ductus arteriosus with naproxen in third trimester. |
| Fertility Effects | Sumatriptan: No known adverse effects on fertility. Naproxen: NSAIDs may inhibit ovulation and delay or prevent follicle rupture due to prostaglandin inhibition; effects are reversible upon discontinuation. |
| Precautions |
| ["Cardiovascular events: Myocardial ischemia, infarction, arrhythmia, and death reported with sumatriptan. NSAIDs increase risk of serious cardiovascular thrombotic events.","Gastrointestinal effects: NSAIDs increase risk of GI bleeding, ulceration, and perforation.","Excessive use: Medication overuse headache may occur.","Serotonin syndrome: Risk with concurrent use of serotonergic drugs.","Renal effects: NSAIDs can cause renal toxicity.","Hypertension: Sumatriptan may increase blood pressure.","Anaphylactic reactions: Serious allergic reactions including anaphylaxis reported with sumatriptan.","Hepatic effects: NSAIDs may cause liver enzyme elevations."] |